Table 1.
Baseline demographic and disease history (FAS).
| Characteristic | N (%) |
|---|---|
| Number of patients | 84 |
| Age, median years (min, max) | 51 (29–78) |
| ≥65 years | 11 (13.1) |
| <65 years | 73 (86.9) |
| Gender, n (%) | |
| Male | 54 (64.3) |
| Female | 30 (35.7) |
| Han ethnicity, n (%) | 81 (96.4) |
| Allergic history, n (%) | 11 (13.1) |
| ECOG PS, n (%) | |
| 0 | 45 (53.6) |
| 1 | 37 (44.0) |
| 2 | 2 (2.4) |
| Time since diagnosis, median years (min, max) | 2.7 (0.1–22.5) |
| Ann Arbor stage, n (%) | |
| Stage II | 5 (6.0) |
| Stage III | 20 (23.8) |
| Stage IV | 59 (70.2) |
| Relapsed case, n (%) | 39 (46.4) |
| Refractory case, n (%) | 14 (16.7) |
| Both relapsed and refractory case, n (%) | 31 (36.9) |
| Median number of prior regimens, n | 4 (2–18) |
| Previous chemotherapy regimens, n (%) | 84 (100.0) |
| Previous anti-CD20 therapy, n (%) | 84 (100.0) |
| Previous radiotherapy treatment, n (%) | 15 (17.9) |
| Previous tumor surgery treatment, n (%) | 7 (8.3) |
| Hematopoietic stem cell transplant, n (%) | 2 (2.4) |
| Previous participation in other clinical trials of anti-tumor therapy, n (%) | 17 (20.2) |
Note: Data are presented as the median (min, max), n (%). The cutoff date for the analysis was September 30, 2021. Baseline was defined as the last non-null observation prior to the first drug administration.